We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Biologic sequelae of c-Jun NH<sub>2</sub>-terminal kinase (JNK) activation in multiple myeloma cell lines.
- Authors
Hideshima, Teru; Hayashi, Toshiaki; Chauhan, Dharminder; Akiyama, Masaharu; Richardson, Paul; Anderson, Kenneth
- Abstract
Although c-Jun NH2-terminal kinase (JNK) is activated by treatment with therapeutic agents, the biologic sequelae of inhibiting constitutive activation of JNK has not yet been clarified. In this study, we examine the biologic effect of JNK inhibition in multiple myeloma (MM) cell lines. JNK-specific inhibitor SP600125 induces growth inhibition via induction of G1 or G2/M arrest in U266 and MM.1S multiple myeloma cell lines, respectively. Neither exogenous IL-6 nor insulin-like growth factor-1 (IGF-1) overcome SP600125-induced growth inhibition, and IL-6 enhances SP600125-induced G2/M phase in MM.1S cells. Induction of growth arrest is mediated by upregulation of p27Kip1, without alteration of p53 and JNK protein expression. Importantly, SP600125 inhibits growth of MM cells adherent to bone marrow stromal cells (BMSCs). SP600125 induces NF-?B activation in a dose-dependent fashion, associated with phosphorylation of I?B kinase a (IKKa) and degradation of I?Ba. In contrast, SP600125 does not affect phosphorylation of STAT3, Akt, and/or ERK. IKK-specific inhibitor PS-1145 inhibits SP600125-induced NF-?B activation and blocks the protective effect of SP600125 against apoptosis. Our data therefore demonstrate for the first time that inhibiting JNK activity induces growth arrest and activates NF-?B in MM cells.Oncogene (2003) 22, 8797-8801. doi:10.1038/sj.onc.1206919
- Subjects
CANCER cells; CELL lines; MULTIPLE myeloma; BONE marrow cells; NF-kappa B
- Publication
Oncogene, 2003, Vol 22, Issue 54, p8797
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/sj.onc.1206919